Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161472 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01161472 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 20 participants.
The verdict
NCT01161472, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The study is designed to evaluate elements of cognitive function in subjects receiving either fesoterodine or alprazolam.
Interventions
- DRUG Placebo
- DRUG 4mg fesoterodine
- DRUG 8mg fesoterodine
- DRUG alprazolam 1mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-07 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01161472
The ClinicalTrials.gov registry entry for NCT01161472 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01161472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01161472 about?
NCT01161472 is a clinical study titled "A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects". The study is designed to evaluate elements of cognitive function in subjects receiving either fesoterodine or alprazolam.
What is the current status of trial NCT01161472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-07. Estimated completion is 2010-09.
What interventions are being tested in trial NCT01161472?
The interventions under investigation include: Placebo (DRUG), 4mg fesoterodine (DRUG), 8mg fesoterodine (DRUG), alprazolam 1mg (DRUG).
Who is sponsoring clinical trial NCT01161472?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.